Electromed, Inc. Fiscal 2016 Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2016, compared with fiscal 2015. The supplied metadata references “2015 Q4,” but the filing is an annual Form 10-K for fiscal 2016, not a quarterly filing.
Business context
Electromed develops, manufactures, and sells SmartVest high-frequency chest wall oscillation systems and related airway-clearance products for patients with compromised pulmonary function. Sales are primarily made in the U.S. home-care market through physician referrals and third-party reimbursement, with additional institutional and international sales. The company operates as a single medical-equipment segment.
Key financial metrics
| Metric | Fiscal 2016 | Fiscal 2015 | Change |
|---|---|---|---|
| Net revenue | $22.992 million | $19.408 million | 18.5% increase |
| Gross profit | $17.876 million | $13.600 million | 31.4% increase |
| Gross margin | 77.7% | 70.1% | 760 basis-point increase |
| Operating income | $3.109 million | $1.310 million | 137.3% increase |
| Net income | $2.213 million | $1.092 million | 102.6% increase |
| Diluted earnings per share | $0.27 | $0.13 | Increase |
| Operating cash flow | $2.167 million | $2.781 million | Decrease |
Home-care revenue increased 20.5% to $20.500 million, institutional revenue increased 14.9% to $1.778 million, and international revenue declined 16.5% to $713,000. U.S. revenue was approximately $22.3 million, of which 92% was home care and 8% institutional.
SG&A expense rose 20.2% to $14.387 million, primarily from higher compensation, bonuses, sales incentives, staffing, professional fees, recruiting, and travel. R&D expense increased to $380,000 from $316,000. Net interest expense declined to $67,000 from $86,000.
Cash increased to $5.123 million from $3.598 million. Total current assets were $15.821 million and current liabilities were $3.073 million, implying working capital of approximately $12.748 million. Accounts receivable increased to $7.611 million and inventory increased to $2.480 million.
Debt, liquidity, and cash flow
- Operating activities generated $2.167 million of cash; investing activities used $580,000, primarily for $535,000 of capital expenditures; financing activities used $62,000.
- The renewed revolving credit facility provides up to $2.5 million, subject to borrowing-base limitations. No revolver balance was outstanding at June 30, 2016, and the full $2.5 million was available.
- Term debt totaled approximately $1.202 million, including a $1.200 million mortgage note bearing interest at 5.0%. Approximately $1.090 million is due at maturity in December 2018.
- The credit arrangements require, among other conditions, minimum tangible net worth of $10.125 million and restrict additional indebtedness and dividends. The company was in compliance at year-end.
- The revolving facility expired on December 18, 2016 if not renewed; the filing states that management expected available liquidity and operating cash flow to support fiscal 2017 requirements.
Material changes versus fiscal 2015
- Revenue growth was driven by higher third-party-payer approval rates, improved reimbursement processes, new payer contracts, faster approval cycles, higher average reimbursement per unit, and increased referrals.
- Gross margin expanded substantially because of the increased mix of domestic home-care revenue and lower SmartVest SQL manufacturing costs.
- Operating expenses grew faster than revenue in several areas, reflecting investment in personnel, sales capacity, reimbursement operations, information technology, and professional services.
- Net income benefited from a $288,000 reduction in tax expense associated with releasing the full valuation allowance on U.S. deferred tax assets.
- Operating cash flow declined despite higher earnings, principally because of a $1.093 million increase in accounts receivable and increases in inventory and prepaid assets.
- The reserve for potentially obsolete SmartVest SV2100 parts was $10,000 in fiscal 2016 versus $110,000 in fiscal 2015.
Guidance, outlook, risks, and unusual items
Management’s fiscal 2017 priorities were profitable growth, higher-quality referrals, improved reimbursement rates, continued product innovation, expanded sales coverage, stronger therapy adherence, broader payer coverage, and increased institutional market share. Management expected R&D spending to increase over the following twelve months.
Management stated that long-term gross margins were expected to remain approximately 75%, although short-term margins may fluctuate with payer mix, diagnosis mix, Medicaid reimbursement, and patient eligibility.
- Revenue depends heavily on Medicare, Medicaid, and private-payer coverage and reimbursement rates. Actual collections may be below allowable amounts because of deductibles, copayments, coverage limitations, or patient nonpayment.
- Revenue recognition includes estimates for selling-price adjustments, doubtful accounts, and long-term installment collections. Unrecognized installment-method sales were approximately $1.977 million at June 30, 2016.
- The company faces competition from other HFCWO devices and alternative airway-clearance therapies.
- FDA, international, quality-system, privacy, healthcare fraud-and-abuse, and reimbursement regulations create compliance and potential enforcement risks.
- A patent covering company technology was scheduled to expire in calendar 2016. The company held 20 U.S. and 13 foreign issued patents and 29 pending applications at year-end.
- The company provides lifetime warranties for qualifying U.S. and Canadian home-care systems and three-year warranties for most institutional and international sales. The warranty reserve was $660,000 at year-end.
- The medical-device excise tax moratorium beginning January 1, 2016 positively affected operating profit.
- The filing reports no material pending litigation and no off-balance-sheet arrangements. The independent auditor issued an unqualified opinion, while no auditor attestation of internal controls was required because Electromed was a smaller reporting company.
Most important facts for investors to verify
- Whether the revolving credit facility was renewed after its December 18, 2016 expiration date and on what terms.
- Whether referral growth, payer approval rates, average reimbursement, and accounts-receivable collections remained favorable after fiscal 2016.
- Whether the fiscal 2016 tax benefit from releasing the deferred-tax valuation allowance is recurring; it appears to be a nonrecurring benefit.
- Whether gross margins can remain near management’s approximately 75% long-term target as payer and product mix changes.
- The collectability and timing of the $1.977 million of unrecognized installment-method sales and the adequacy of related receivable and warranty reserves.
- The effect of reimbursement-policy changes, regulatory developments, competition, patent expirations, and international sales trends on future growth.